Amneal Pharmaceuticals, Inc.
A maker of generic and specialty medicines, Amneal Pharmaceuticals develops, manufactures and distributes hundreds of medications—from pills and injections to eye drops, creams and transdermal patches—that patients and pharmacies use every day. Founded in 2002 by brothers Chirag and Chintu Patel, the company grew from a bootstrapped family venture in New Jersey into one of the largest generic drugmakers in the United States. Fun fact: the name "Amneal" blends the founders' names, Amar and Neal.
Granted 886.5K
Granted 886.5K
Granted 34.8K
Granted 48.7K
Granted 633.9K
Granted 508.5K
Granted 34.8K
Granted 34.8K
Granted 34.8K
Granted 34.8K
Granted 549.0K
Granted 426.8K
Granted 34.8K
Granted 34.8K · Sold 34.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Patel ChintuCo-CEO, Director · 6 transactions | +2% | 26.17M | 886.5K | — | — |
| Patel Chirag K.President & Co-CEO, Director · 6 transactions | +2.4% | 22.66M | 886.5K | — | — |
| Patel GautamDirector · 1 transaction | +2.2% | 1.64M | 34.8K | — | — |
| Meister Paul MDirector · 1 transaction | +6.2% | 832.8K | 48.7K | — | — |
| Konidaris TasosExecutive Vice President & CFO · 10 transactions | +267.9% | 449.4K | 633.9K | — | — |
| Shah NikitaExecutive Vice President · 10 transactions | +173.1% | 399.8K | 508.5K | — | — |
| George Jeffrey P.Director · 1 transaction | +11.2% | 344.6K | 34.8K | — | — |
| Buchi J KevinDirector · 1 transaction | +11.5% | 337.1K | 34.8K | — | — |
| Nark Ted CDirector · 1 transaction | +12% | 325.8K | 34.8K | — | — |
| Yanai ShlomoDirector · 1 transaction | +12.2% | 320.8K | 34.8K | — | — |
| Boyer Andrew SExecutive Vice President · 11 transactions | +79.5% | 273.6K | 549.0K | — | — |
| Daly Jason B.EVP, Chief Legal Officer · 10 transactions | +2420.9% | 267.4K | 426.8K | — | — |
| Kiely JohnDirector · 1 transaction | +15.4% | 260.3K | 34.8K | — | — |
| Autor Deborah M.Director · 2 transactions | 0% | 93.7K | 34.8K | — | 34.8K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -34.8K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.